Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000152
Chunk: 7

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 7
---
 |
| Rare Diseases |     |           |   388.7 |     |            |   380.5 |     |          |   -8.2 |     |          |  -2.1 | % |     |     |   0.7 | %                         |
| PDT           |     |           |   535.7 |     |            |   517.4 |     |          |  -18.2 |     |          |  -3.4 | % |     |     |   0.4 | %                         |
| Oncology      |     |           |   285.0 |     |            |   287.8 |     |          |    2.8 |     |          |   1.0 | % |     |     |   3.4 | %                         |
| Vaccines      |     |           |    38.1 |     |            |    31.7 |     |          |   -6.5 |     |          | -16.9 | % |     |     | -16.8 | %                         |
| Neuroscience  |     |           |   314.6 |     |            |   206.1 |     |          | -108.4 |     |          | -34.5 | % |     |     | -32.1 | %                         |
| Other         |     |           |   126.8 |     |            |   103.1 |     |          |  -23.7 |     |          | -18.7 | % |     |     | -17.5 | %                         |
| Total         |     |           | 2,384.0 |     |            | 2,219.5 |     |          | -164.5 |     |          |  -6.9 | % |     |     |  -3.9 | %                         |

Year-on-year change in revenue for this six-month period in each of our business areas was primarily attributable to the following products:

#### GI
In GI, revenue was JPY 692.8 billion (JPY -2.4 billion and -0.3% AER, +3.2% CER).

Sales of RESOLOR/MOTEGRITY (for chronic idiopathic constipation) were JPY 3.6 billion (JPY -7.6 billion and -67.7